TOXICITY OF COMBINED BEVACIZUMAB-LOMUSTINE TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM): REPORT FROM A RANDOMIZED PHASE II STUDY

被引：0
|
作者：
van den Bent, Martin
Taal, Walter
Sleijfer, Stefan
van Heuvel, Irene
SillevisSmitt, Peter A.
Bromberg, Jacoline E.
Vernhout, Irene
机构：
来源：
NEURO-ONCOLOGY | 2010年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [1] Randomized phase II study of axitinib alone or combined with lomustine in patients with recurrent glioblastoma.
    Duerinck, Johnny
    Du Four, Stephanie
    Bouttens, Frank
    Verschaeve, Vincent
    Andre, Chantal
    Van Fraeyenhove, Frank
    Chaskis, Cristo
    D'Haene, Nicky
    Le Mercier, Marie
    Salmon, Isabelle
    Neyns, Bart
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients
    Jakobsen, J. N.
    Urup, T.
    Grunnet, K.
    Toft, A.
    Johansen, M. D.
    Poulsen, S. H.
    Christensen, I. J.
    Muhic, A.
    Poulsen, H. S.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (02) : 439 - 446
  • [3] Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients
    J. N. Jakobsen
    T. Urup
    K. Grunnet
    A. Toft
    M. D. Johansen
    S. H. Poulsen
    I. J. Christensen
    A. Muhic
    H. S. Poulsen
    [J]. Journal of Neuro-Oncology, 2018, 137 : 439 - 446
  • [4] A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study
    Taal, Walter
    Oosterkamp, Hendrika M.
    Walenkamp, Annemiek M. E.
    Beerepoot, Laurens Victor
    Hanse, Monique
    Buter, J.
    Honkoop, Aafke
    Boerman, Dolf
    De Vos, Filip Yves Francine Leon
    Jansen, Rob L.
    van den Berkmortel, Franchette W. P. J.
    Brandsma, Dieta
    Kros, Johan M.
    Bromberg, Jacoline E.
    van Heuvel, Irene
    Smits, Marion
    van der Holt, Bronno
    Vernhout, Rene
    Van den Bent, Martin J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] TOXICITY AND EFFICACY OF LOMUSTINE PLUS BEVACIZUMAB IN RECURRENT GLIOBLASTOMA PATIENTS
    Jakobsen, Jan Nyrop
    Urup, Thomas
    Grunnet, Kirsten
    Christensen, Ib Jarle
    Villingshoj, Mette
    Poulsen, Hans Skovgaard
    [J]. NEURO-ONCOLOGY, 2017, 19 : 6 - 6
  • [6] RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM)
    Gilbert, M. R.
    Wang, M.
    Aldape, K.
    Lassman, A.
    Sorensen, A. G.
    Mikkelson, T.
    Groves, M.
    Werner-Wasik, M.
    Regine, W.
    Mehta, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma
    Brandes, Alba A.
    Carpentier, Antoine F.
    Kesari, Santosh
    Sepulveda-Sanchez, Juan M.
    Wheeler, Helen R.
    Chinot, Olivier
    Cher, Lawrence
    Steinbach, Joachim P.
    Capper, David
    Specenier, Pol
    Rodon, Jordi
    Cleverly, Ann
    Smith, Claire
    Gueorguieva, Ivelina
    Miles, Colin
    Guba, Susan C.
    Desaiah, Durisala
    Lahn, Michael M.
    Wick, Wolfgang
    [J]. NEURO-ONCOLOGY, 2016, 18 (08) : 1146 - 1156
  • [8] A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
    Sepulveda, J. M.
    Belda-Iniesta, C.
    Gil-Gil, M.
    Perez-Segura, P.
    Berrocal, A.
    Reynes, G.
    Gallego, O.
    Capellades, J.
    Ordonez, J. M.
    La Orden, B.
    Balana, C.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09): : 743 - 750
  • [9] A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
    J. M. Sepúlveda
    C. Belda-Iniesta
    M. Gil-Gil
    P. Pérez-Segura
    A. Berrocal
    G. Reynés
    O. Gallego
    J. Capellades
    J. M. Ordoñez
    B. La Orden
    C. Balañá
    [J]. Clinical and Translational Oncology, 2015, 17 : 743 - 750
  • [10] Phase II trial of bevacizumab and erlotinib in recurrent glioblastoma multiforme (GBM)
    Sathornsumetee, Sith
    Vredenburgh, James
    Rich, Jeremy
    Desjardins, Annick
    Quinn, Jennifer
    Bota, Daniela
    Goli, Krishna
    Mathe, Alyssa
    Gururangan, Sridharan
    Friedman, Allan
    Friedman, Henry
    Reardon, David
    [J]. NEURO-ONCOLOGY, 2007, 9 (04) : 516 - 516
12345